Dr. Alan P. Baptist, MD

Medicare patients and services

Medicare patients, 2024

27

Services billed

68

Patients’ average age

68

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 14 companies reported 60 payments worth $40,319 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Michigan →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $136,918 in research payments for these studies, mostly to the institutions running them.

• A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
  Teva Pharmaceuticals USA, Inc.
• Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
  AstraZeneca Pharmaceuticals LP
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06572228
• Omalizumab for food allergy – understanding patient and provider perspectives
  Genentech, Inc.
• A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma
  Incyte Corporation
• The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
  AstraZeneca Pharmaceuticals LP
• A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participan…
  AstraZeneca Pharmaceuticals LP
• Study name not reported
  Ionis Pharmaceuticals, Inc.
• Registry of Asthma Patients Initiating DUPIXENT®
  Regeneron Pharmaceuticals, Inc. · Completed · NCT04287621
• A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
  Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Allergy & Immunology clinicians in Ann Arbor

• Ulus Atasoy, MD
• James R. Baker JR., MD
• James L. Baldwin, MD
• Ruizhi Dong, MD
• Sara S. Ellingwood, M.D.
• Lauren Franzblau, MD
• George E. Freigeh, MD
• Emma Greimann, MD